Clopidogrel is an oral antiplatelet drug that can be used for the prevention and treatment of complications caused by myocardial infarction, ischemic cerebral thrombosis, vasculitis obliterans, atherosclerosis and thromboembolism. In clinical work, it has been found that not all patients can obtain the expected effect in the application of clopidogrel, which is manifested as the occurrence of cardiovascular adverse events, a phenomenon known as "clopirorazor resistance". In addition, there was a risk of bleeding with clopidogrel, with a rate of 1.4% of serious bleeding events. Clopidogrel resistance is mainly due to CYP2C19 gene mutation which reduces the active metabolite of clopidogrel.

This kit detects the polymorphisms of CYP2C19 gene (CYP2C19*2, CYP2C19*3, CYP2C19*17), determines the type of patient's metabolism of clopidogrel, so as to guide the drug use of clopirollet and reduce the disease caused by the resistance to clopirollet. delay or risk of bleeding to the patient due to the hypermetabolized form of clopidogrel.

This product has been approved by my country's CFDA

Registration certificate number: National Machinery Note 20163401515